Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care for wet AMD is vascular endothelial growth factor (VEGF) inhibitors, namely Genentech’s Lucentis, approved for wet AMD; Genentech’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD; and, most recently, Regeneron’s Eylea. Eylea has experienced rapid and continued uptake due to its favorable attributes. Ahead of the expected entry of new VEGF inhibitors brolucizumab (Novartis) and abicipar pegol (Allergan) to the U.S. wet AMD therapy market, it is essential to understand the current state of the wet AMD market from the perspective of U.S. retinal specialists/ophthalmologists, including their perceptions related to the current anti-VEGF agents for wet AMD.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Markets covered: United States
Primary research: Survey of 99 ophthalmologists/retinal specialists in the United States.
Key companies: Genentech, Regeneron, Valeant Pharmaceuticals
Key drugs: Avastin, Eylea, Lucentis, Macugen, Visudyne
Key insights provided: